Medical Systems Biology Center for Complex Diseases, Affiliated Hospital of Qingdao University, Qingdao, China.
School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
J Cell Mol Med. 2019 Jan;23(1):4-20. doi: 10.1111/jcmm.13564. Epub 2018 Nov 15.
Poria cocos is an edible medicinal fungus known as "Fuling" in Chinese and has been used as a Chinese traditional medicine for more than two thousand years. Pharmacological studies reveal that polysaccharide is the most abundant substance in Poria cocos and has a wide range of biological activities including antitumour, immunomodulation, anti-inflammation, antioxidation, anti-ageing, antihepatitis, antidiabetics and anti-haemorrhagic fever effects. As a result, "Poria cocos polysaccharide oral solution" was developed and sold as an over-the-counter health supplement since 1970s. In 2015, "Polysaccharidum of Poria cocos oral solution" was approved as a drug by Chinese Food and Drug Administration for treating multiple types of cancers, hepatitis and other diseases alone or during chemo- or radiation therapy for patients with cancer. In this article, biochemical, preclinical and clinical studies of Poria cocos polysaccharide from 72 independent studies during the past 46 years (1970-2016) based on PubMed, VIP (Chongqing VIP Chinese Scientific Journals Database), CNKI (China National Knowledge Infrastructure) and Wanfang database searches are summarized. The structure, pharmacological effects, clinical efficacy, immunobalancing molecular mechanism and toxicity of Poria cocos polysaccharide are deliberated to provide a general picture of Poria cocos polysaccharide as a clinically used antitumour drug.
茯苓是一种食用药用真菌,中文名为“茯苓”,已有两千多年的药用历史。药理研究表明,多糖是茯苓中含量最丰富的物质,具有广泛的生物活性,包括抗肿瘤、免疫调节、抗炎、抗氧化、抗衰老、抗肝炎、抗糖尿病和抗出血热作用。因此,自 20 世纪 70 年代以来,“茯苓多糖口服液”已被开发并作为非处方药销售。2015 年,“茯苓多糖口服液”被中国食品药品监督管理局批准为一种药物,可单独或在癌症患者化疗或放疗期间用于治疗多种癌症、肝炎等疾病。本文总结了过去 46 年(1970-2016 年)72 项独立研究中基于 PubMed、VIP(重庆 VIP 中文科技期刊数据库)、CNKI(中国知识基础设施)和万方数据库检索的茯苓多糖的生化、临床前和临床研究。讨论了茯苓多糖的结构、药理作用、临床疗效、免疫平衡分子机制和毒性,为茯苓多糖作为一种临床应用的抗肿瘤药物提供了一个总体概况。